Trial intelligence / Profile preview

Tirzepatide plus basal insulin vs placebo in Chinese adults with type 2 diabetes

CTR20230122Phase 3Completed

Sponsor
Eli Lilly and Company
Start
Jan 2023
Modality
Recombinant Proteins and Enzymes, Peptides
Countries
1
01

Overview

A Phase 3 trial of tirzepatide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jan 2023; status: completed.

02

Drugs

03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on CTR20230122.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20230122.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call